Tandem Diabetes Care Starts Enrollment in Trial

Tandem Diabetes Care, a medical device company, said Tuesday it has begun enrolling patients in a trial for its t:slim X2 Insulin Pump using predictive low glucose suspend technology.

The insulin pump system is designed to suspend insulin delivery when low blood glucose is predicted and subsequently resume insulin delivery when glucose levels begin to rise. The primary endpoint of the study is to demonstrate a reduction in the percentage of CGM values below 70 mg/dL. “The start of this pivotal trial is another important step forward in our automated insulin delivery programs, and comes on the heels of very encouraging feasibility study data,” said CEO Kim Blickenstaff, “We remain on track to submit our t:slim X2 Pump with predictive low glucose suspend to the [Food and Drug Administration] in early 2018.”

Leave A Reply

Your email address will not be published.